We found that before starting Rituximab therapy, CD4+CD25+ lymphocytes from patients with SLE showed a variable capability to inhibit the proliferation of autologous CD4+CD25- cells (CD4+CD25+:CD4+CD25- ratio 1:10) stimulated with PHA (Figure 3). Here, CD4 is linked to systemic lupus erythematosus.